Clinical Research Directory

Inclusion Criteria: * Adult male patients (age ≥18 years) * Documented histopathology or cytopathology of metastatic prostate adenocarcinoma * Confirmed castration-resistant status, defined as disease progression despite castrate levels of serum testosterone (\<50 ng/dL or \<1.7 nmol/L), as demonstrated by radiographic progression, PSA progression, or symptomatic progression * Prior exposure to an NHA in earlier settings. * Planned or prior initiation of Olaparib + Abiraterone in the 1st line mCRPC setting as per routine clinical practice. * Patients who are willing and able to sign an informed consent and are either currently receiving or are planned to initiate Olaparib + Abiraterone per routine clinical practice. Exclusion Criteria: * -Prior exposure to a Poly (ADP-ribose) Polymerase Inhibitor (PARPi), including Olaparib, Rucaparib, Niraparib, or Talazoparib. * Patients who received or progressed on abiraterone in previous lines of treatment before mCRPC diagnosis (e.g., in metastatic hormone-sensitive prostate cancer \[mHSPC\]). * Participation in an investigational clinical trial with another prostate cancer therapy within 30 days prior to Olaparib initiation. * Life expectancy \<3 months (unrelated to mCRPC) that could interfere with study outcomes * Known hypersensitivity to Olaparib, Abiraterone, or their excipients. * Uncontrolled medical conditions that may compromise participation or data interpretation, in the opinion of the Investigator (e.g., severe hepatic impairment, active infections). * Any psychiatric or cognitive conditions that may interfere with the patient's ability to consent or comply with study procedures.